Results 51 to 60 of about 14,237 (205)
BET Protein Inhibition Regulates Macrophage Chromatin Accessibility and Microbiota-Dependent Colitis
Frontiers in Immunology, 2022 IntroductionIn colitis, macrophage functionality is altered compared to normal homeostatic conditions. Loss of IL-10 signaling results in an inappropriate chronic inflammatory response to bacterial stimulation.
Michelle Hoffner O’Connor +27 more
doaj +1 more source
Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
eLife, 2017 In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "BET bromodomain inhibition as a therapeutic strategy
Fraser Aird +3 more
doaj +1 more source
BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell. [PDF]
PLoS ONE, 2016 Displacement of Bromodomain and Extra-Terminal (BET) proteins from chromatin has promise for cancer and inflammatory disease treatments, but roles of BET proteins in metabolic disease remain unexplored.
Jude T Deeney +4 more
doaj +1 more source
JQ1(+) treatment increases the MCV replication.
, 2012 A. JQ1(+) releases Brd4 from chromatin. C33A cells were treated with 300 nM JQ1(+), JQ1(−) or DMSO for 24 h. Cells were fixed and stained with Brd4 antibody and DAPI. B. JQ1(+) treatment increases the MCV replication.
Jianxin You (121729) +5 more
core +1 more source
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
Molecular Oncology, EarlyView.Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni +11 more
wiley +1 more source
Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
PLoS ONE, 2014 High level MYC expression is associated with almost all human cancers. JQ1, a chemical compound that inhibits MYC expression is therapeutically effective in preclinical animal models in midline carcinoma, and Burkitt's lymphoma (BL). Here we show that JQ1 does not inhibit MYC expression to a similar extent in all tumor cells. The BL cells showed a ∼90%
Fowler, Trent +8 more
openaire +6 more sources
JQ1 reduces intracellular lipid in INS-1 cells.
, 2016 (A) Images are of INS-1 cells incubated with indicated concentrations of JQ1 for 3 days and stained with Nile Red. Results are from a single representative experiment repeated 5 times. Lipid droplets appear as bright dots within cells in micrographs (40X
Orian S. Shirihai (256826) +4 more
core +1 more source
Pharmacokinetic studies of (+)-JQ1, SAHA, and 009P1 in mice.
, 2023 Pharmacokinetic studies of (+)-JQ1, SAHA, and 009P1 in mice.
Tran Phuc (3948350) +10 more
core +1 more source
Advanced Robotics Research, EarlyView.An AI‐powered, robot‐assisted framework automatically produces, images, and analyzes 3D tumor spheroids to evaluate drug efficacy. Integrated modules handle spheroid formation, live/dead staining, brightfield imaging, and automated image analysis, including spheroid segmentation, viability and metrics to assess the drug treatment efficacy. The workflow
Dalia Mahdy +13 more
wiley +1 more source
Bewertung der Kombinationsbehandlung Docetaxel und JQ1 in präklinischen 2D- und 3D-Modellen von Prostatakrebs [PDF]
, 2023 Prostate cancer (PCa) remains the most prevalent cancer in men globally, with an increasing burden worldwide. PCa is unique in its dependence on androgen-androgen receptor (AR) signaling for growth and progression, and hormonal therapies have greatly ...
Xu, Yipeng
core +1 more source